Skip to Main Content

WASHINGTON — The legislative saga on drug pricing is mostly over for now, but drug pricing policy will still offer plenty of controversy in 2023.

Agencies will work to implement a massive bureaucratic structure of the Inflation Reduction Act. Drugmakers who manufacture high-cost drugs will be put on the spot in a brand-new price negotiation process. Medicare will face big decisions about how to cover new drugs, and a divided Congress will be left with the leftovers of what Democrats couldn’t accomplish.


STAT has rounded up the important dates and policies to watch this year for everyone from policy wonks to patients.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.